Reported Thursday, HUTCHMED Confirms ORPATHYS (Savolitinib) Retains Spot On China's National Reimbursement Drug List
Reported Thursday, HUTCHMED Confirms ORPATHYS (Savolitinib) Retains Spot On China's National Reimbursement Drug List
據報道，華大基因確認ORPATHYS（沙沃替尼）在中國國家醫保藥品目錄中保留了其地位
ORPATHYS is an oral, potent, and highly selective MET tyrosine kinase inhibitor ("TKI"). It received conditional approval in China in June 2021 for the treatment of certain patients with non-small cell lung cancer ("NSCLC") with MET exon 14 skipping alterations. More than a third of the world's lung cancer patients are in China and, among those with NSCLC globally, approximately 2-3% have tumors with MET exon 14 skipping alterations.
ORPATHYS是一種口服的、有效的且高度選擇性的MEt酪氨酸激酶抑制劑（"TKI"）。它於2021年6月在中國獲得有條件批准，用於治療某些患有MEt外顯子14跳躍變異的非小細胞肺癌（"NSCLC"）患者。全球有超過三分之一的肺癌患者在中國，而在全球的NSCLC患者中，約有2-3%存在MEt外顯子14跳躍變異的腫瘤。
資訊熱榜
更新時間